KSKatayoun Samimi-Rad

Katayoun Samimi-Rad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katayoun Samimi-Rad has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bioinformatics Analysis of Persistent Dysregulated Expression of Genes Involved in HCV‐Induced Neurological Disorders and Liver Injuries After DAA Treatment Through Weighted Gene Co‐Expression Network Analysis

    by Mohadeseh Zarei Ghobadi, Mohammad Amin Nooraniyan Esfehani, Shohreh Shahmahmoodi, Ahmad Nejati, Abolfazl Keshavarz, Katayoun Samimi‐Rad

    Background and Aims: The molecular processes involved in the progression of neuropsychiatric and liver disorders in some patients who have achieved sustained virologic response after successful DAA treatment are still unclear. To understand these processes, we investigated alterations in the transcription patterns of genes associated with neural and immune functions after DAA therapy. Methods: A total of six microarray gene expression datasets related to patients who had received DAA treatment were downloaded from the Gene Expression Omnibus. Three groups comprising pretreatment and posttreatment CHC patients, as well as healthy subjects, were considered for the analysis. A weighted gene co‐expression network analysis was then performed to identify the gene groups (modules) implicated in chronic hepatitis C before and after DAA treatment. Differential gene expression (DEG) analysis and protein–protein interaction network (PPIN) analysis were then used to determine the major dysregulated genes before and after treatment. Results: The common genes identified between the DEGs and selected modules, as well as further PPIN analysis, revealed the non‐normalization of novel neural‐related genes, including IRF3, FYN, CFL1, TGFβ1, DPYSL2, CDK5, and GIT1, as well as novel immune‐related genes, including IκBα, CD14, IL‐1β, IRAK1, TBK1, and CEBPB, after DAA treatment. Conclusions: Our findings suggest that DAA treatment does not lead to the normalization of gene transcription patterns in CHC patients up to 6 months after HCV clearance. The non‐normalization of neuronal and immune gene expression, along with subsequent changes in the activity of related pathways, may contribute to the persistence or progression of HCV‐induced neuropsychiatric disorders and liver injuries after DAA treatment. The identified genes and their altered expression patterns provide novel insights into potential molecular mechanisms underlying disease progression following successful DAA therapy. Furthermore, these genes may serve as candidate biomarkers for monitoring disease progression or as potential targets for therapeutic intervention.

  • Open Access

    New insights into potential biomarkers and their roles in biological processes associated with hepatitis C-related liver cirrhosis by hepatic RNA-seq-based transcriptome profiling

    by Hossein Nasr Azadani, Mohssen Nassiri Toosi, Shohreh Shahmahmoodi, Ahmad Nejati, Hamzeh Rahimi, Mohammad Farahmand, Abolfazl Keshavarz, Fatemeh Ghorbani Motlagh, Katayoun Samimi-Rad


  • Open Access

    BacMam virus-based surface display for HCV E2 glycoprotein induces strong cross-neutralizing antibodies and cellular immune responses in vaccinated mice

    by Ebrahim Kord, Farzin Roohvand, Jean Dubuisson, Thibaut Vausselin, Hosein Nasr Azadani, Abolfazl Keshavarz, Ahmad Nejati, Katayoun Samimi-Rad

    Background: Despite recent advancements, limitations in the treatment and control of hepatitis C virus (HCV) infection reprioritized the studies for invention of an efficient HCV vaccine to elicit strong neutralizing antibodies (NAbs) and cellular responses. Methods: Herein, we report molecular construction of a BacMam virus-based surface display for a subtype-1a HCV gpE2 (Bac-CMV-E2-gp64; Bac) that both expressed and displayed gpE2 in mammalian cells and bacouloviral envelope, respectively. Results: Assessments by western blotting, Immunofluorescence and Immunogold-electron microscopy indicated the proper expression and incorporation in insect cell and baculovirus envelope, respectively. Mice immunized in three different prime-boost immunization groups of: Bac/Bac, Bac/Pro (bacoulovirus-derived gpE2) and Bac/DNA (plasmid DNA (pCDNA)-encoding gpE2) developed high levels of IgG and IFN-γ (highest for Bac/Bac group) indicating the induction of both humeral and cellular immune responses. Calculation of the IgG2a/IgG1 and IFN-γ/IL-4 ratios indicated a Th1 polarization of immune responses in the Bac/Bac and Bac/DNA groups but a balanced Th1-Th2 phenotype in the Bac/Pro group. Sera of the mice in the Bac/Bac group provided the highest percentage of cross-NAbs against a subtype-2a HCVcc (JFH1) compared to Bac/Pro and Bac/DNA groups (62% versus 41% and 6%). Conclusions: Results indicated that BacMam virus-based surface display for gpE2 might act as both subunit and DNA vaccine and offers a promising strategy for development of HCV vaccine for concurrent induction of strong humoral and cellular immune responses.


  • Open Access

    HCV Core/NS3 Protein Immunization with “N-Terminal Heat Shock gp96 Protein (rNT (gp96))” Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice

    by Zamaneh Hajikhezri, Farzin Roohvand, Monireh Maleki, Shohreh Shahmahmoodi, Ali Akbar Amirzargar, Abolfazl Keshavarz, Negar Seyed, Mohammad Farahmand, Katayoun Samimi-Rad

    Feeble cellular responses induced by T cell-based vaccines are a major challenge for the development of an effective vaccine against Hepatitis C virus (HCV) infection. To address this challenge, the potential of N-terminal fragment of gp96 heat shock protein (rNT (gp96) as an adjuvant was evaluated and compared to that of the CpG (as a recognized Th1-type adjuvant) in the formulation of HCV core/NS3 antigens in three immunization strategies of protein/protein, DNA/DNA, and DNA/protein. Immunized mice were evaluated for elicited immune responses in week 3 (W3) and 11 post-immunizations. Our results demonstrated that the protein (subunit) vaccine formulated with rNT (gp96) in protein/protein strategy (core/NS3 + gp96) was significantly more efficient than CpG oligodeoxynucleotides (CpG ODN) formulation and all other immunization strategies in the induction of Th1-type cytokines. This group of mice (core/NS3 + gp96) also elicited a high level of anti-Core-NS3 total immunoglobulin G (IgG) with dominant IgG2a isotype at W3. Thus, the co-administration of recombinant NT (gp96) protein with rHCV proteins might be a promising approach in the formulation of HCV subunit vaccine candidates for induction of high levels of Th1 cytokines and humoral responses.


  • A non-pathogenic Leishmania tarentolae vector based- HCV polytope DNA vaccine elicits potent and long lasting Th1 and CTL responses in BALB/c mice model

    by Nastaran Ansari, Sima Rafati, Tahereh Taheri, Farzin Roohvand, Mohammad Farahmand, Zamaneh Hajikhezri, Abolfazl Keshavarz, Katayoun Samimi-Rad


  • Open Access

    Repression of the Internal Ribosome Entry Site-dependent Translation of Hepatitis C Virus by an Engineered PUF Protein

    by Seyed Jalal Kiani, Tahereh Taheri, Ahmad Nejati, Monireh Maleki, Sima Rafati, Kayhan Azadmanesh, Seyed Moayed Alavian, Talat Mokhtari Azad, Katayoun Samimi-Rad

    Background: Pumilio/fem-3 mRNA binding factor (PUF) proteins can bind RNA in a sequence-specific manner. The deciphered RNA-recognition code of these proteins has enabled researchers to design engineered PUF proteins, capable of binding to any desired target in order to modify its ultimate fate. In this study, a modified Homo sapiens Pumilio 1-homology domain (HsPUM1-HD) was engineered to bind to the internal ribosome entry site (IRES) of hepatitis C virus (HCV) genome to potentially inhibit viral translation. Methods: Based on the RNA-recognition code, required modifications were applied to HsPUM1-HD in order to change its natural recognition sequence to a sequence in the stem-loop III of HCV IRES. RNA protein pull-down assay was performed to assess the sequence specificity of the modified HsPUM1-HD (mHsPUM1-HD). Translational inhibitory effect of mHsPUM1-HD was evaluated in a dual-luciferase reporter assay. Results: The mHsPUM1-HD was found to bind to its cognate RNA in a sequence-specific manner, as a biotinylated target RNA captured mHsPUM1-HD through binding to streptavidin magnetic beads. This protein also reduced HCV IRES-dependent firefly luciferase translation by 40% in HEK293 cells. Conclusions: The present study is the first report of an engineered HsPUM1-HD with potential anti-HCV activity. These findings suggest that PUM-HDs can be engineered to target desired RNAs of infectious agents in order to specifically interrupt protein translation, as an essential step of their life cycle. Keywords: Hepatitis C Virus; Pumilio Protein; Internal Ribosome Entry Sites


  • PUF Proteins: Cellular Functions and Potential Applications

    by Seyed Kiani, Tahereh Taheri, Sima Rafati, Katayoun Samimi-Rad

    RNA-binding proteins play critical roles in the regulation of gene expression. Among several families of RNA-binding proteins, PUF (Pumilio and FBF) proteins have been the subject of extensive investigations, as they can bind RNA in a sequence-specific manner and they are evolutionarily conserved among a wide range of organisms. The outstanding feature of these proteins is a highly conserved RNA-binding domain, which is known as the Pumilio-homology domain (PUM-HD) that mostly consists of eight tandem repeats. Each repeat recognizes an RNA base with a simple three-letter code that can be programmed in order to change the sequence-specificity of the protein. Using this tailored architecture, researchers have been able to change the specificity of the PUM-HD and target desired transcripts in the cell, even in subcellular compartments. The potential applications of this versatile tool in molecular cell biology seem unbounded and the use of these factors in pharmaceutics might be an interesting field of study in near future.


  • Open Access

    Epidemic History of Hepatitis C Virus among Patients with Inherited Bleeding Disorders in Iran

    by Katayoun Samimi-Rad, Ramin Rahimnia, Mahdi Sadeghi, Seyed Amir Malekpour, Mona Marzban, Maryam Keshvari, Seyed Jalal Kiani, Seyed-Moayed Alavian

    The high rate of hepatitis C virus (HCV) infection among transfusion related risk groups such as patients with inherited bleeding disorders highlighting the investigation on prevalent subtypes and their epidemic history among this group. In this study, 166 new HCV NS5B sequences isolated from patients with inherited bleeding disorders together with 29 sequences related to hemophiliacs obtained from a previous study on diversity of HCV in Iran were analyzed. The most prevalent subtype was 1a (65%), followed by 3a (18.7%),1b (14.5%),4(1.2%) and 2k (0.6%). Subtypes 1a and 3a showed exponential expansion during the 20th century. Whereas expansion of 3a started around 20 years earlier than 1a among the study patients, the epidemic growth of 1a revealed a delay of about 10 years compared with that found for this subtype in developed countries. Our results supported the view that the spread of 3a reached the plateau 10 years prior to the screening of blood donors for HCV. Rather, 1a reached the plateau when screening program was implemented. The differences observed in the epidemic behavior of HCV-1a and 3a may be associated with different transmission routes of two subtypes. Indeed, expansion of 1a was more commonly linked to blood transfusion, while 3a was more strongly associated to drug use and specially IDU after 1960. Our findings also showed HCV transmission through blood products has effectively been controlled from late 1990s. In conclusion, the implementation of strategies such as standard surveillance programs and subsiding antiviral treatments seems to be essential to both prevent new HCV infections and to decline the current and future HCV disease among Iranian patients with inherited bleeding disorders.


  • Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran

    by Katayoun Samimi-Rad, Farzin Sadeghi, Aliakbar Amirzargar, Mohamad Reza Eshraghian, Seyed-Moayed Alavian, Ramin Rahimnia

    There is no published data on association of HLA class II alleles with clearance or persistence after acute hepatitis C virus (HCV) infection in patients from Iran. HLA DRB1, DQA1, and DQB1 alleles were determined using polymerase chain reaction amplification with sequence specific primers (PCR‐SSP) on a total of 117 thalassemia patients (63 with chronic infection, and 54 with viral clearance) and 120 healthy controls. HLA‐DRB1*0301 and DQA1*0501 alleles were found significantly present in patients with HCV clearance compared to those with chronic infection (P = 0.03 and P = 0.0007, respectively). By contrast, DRB1*0701, DQA1*0201, and DQB1*0602 alleles occurred significantly in those with chronic infection compared to those with viral clearance (P = 0.004, P = 0.007, and P = 0.02, respectively). As compared to the controls, DRB1*0301, DRB1*11, DQA1*0501, and DQB1*0301 alleles showed a significant decrease in chronic patients (P = 0.002, P = 0.001, P = 0.0001, and P = 0.0004, respectively). Furthermore, the haplotype frequencies of DRB1*0301, DQA1*0501, DQB1*0201, and DRB1*1101, DQA1*0501, DQB1*0301 were found significantly higher (P = 0.004 and P = 0.04, respectively) in patients with HCV clearance than those with chronic infection. By contrast, the haplotype DRB1*0701, DQA1*0201, DQB1*0201 occurred more frequently (P = 0.02) in those with chronic infection compared with those with viral clearance. These findings suggest that particular HLA alleles and related haplotypes may have an influence on the outcome of HCV infection among the Iranian patients. Some of the HLA alleles found in the Iranian patients are different from those reported elsewhere, suggesting that the immunogenetic makeup for HCV clearance or persistence may vary based on the ethnicity. J. Med. Virol. 87:1565–1572, 2015.


  • Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96

    by Leila Pishraft-Sabet, Anna D. Kosinska, Sima Rafati, Azam Bolhassani, Tahereh Taheri, Arash Memarnejadian, Seyed-Moayed Alavian, Michael Roggendorf, Katayoun Samimi-Rad

    Induction of a strong hepatitis C virus (HCV)-specific immune response plays a key role in control and clearance of the virus. A polytope (PT) DNA vaccine containing B- and T-cell epitopes could be a promising vaccination strategy against HCV, but its efficacy needs to be improved. The N-terminal domain of heat shock protein gp96 (NT(gp96)) has been shown to be a potent adjuvant for enhancing immunity. We constructed a PT DNA vaccine encoding four HCV immunodominant cytotoxic T lymphocyte epitopes (two HLA-A2- and two H2-Dd-specific motifs) from the Core, E2, NS3 and NS5B antigens in addition to a T-helper CD4+ epitope from NS3 and a B-cell epitope from E2. The NT(gp96) was fused to the C- or N-terminal end of the PT DNA (PT-NT(gp96) or NT(gp96)-PT), and their potency was compared. Cellular and humoral immune responses against the expressed peptides were evaluated in CB6F1 mice. Our results showed that immunization of mice with PT DNA vaccine fused to NT(gp96) induced significantly stronger T-cell and antibody responses than PT DNA alone. Furthermore, the adjuvant activity of NT(gp96) was more efficient in the induction of immune responses when fused to the C-terminal end of the HCV DNA polytope. In conclusion, the NT(gp96) improved the efficacy of the DNA vaccine, and this immunomodulatory effect was dependent on the position of the fusion.